All stock lists
Parabilis Medicines, Inc. (NASDAQ:PBLS)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$27.48-$0.21 (-0.74%)
Market cap
$3.35B
Insider Score
Health Score
Listed since
Jun 10, 2026
Website
Insider Score
––Not scored
PBLS Insider Score
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
Financial Health Score
Fair
From PBLS’s reported statements · Q3 2026 (trailing 12 months)
Profitability0 / 20
Loses money on what it sells.
- Revenue
- $2.3M
- Net income
- -$177.1M
- Net margin
- -7828.5%
Leverage20 / 20
Little or no net debt.
- Total debt
- $39.8M
- Cash
- $521.2M
- Debt / equity
- 0.04
Liquidity20 / 20
Comfortably covers what is due within a year.
- Current assets
- $879.0M
- Current liabilities
- $68.3M
- Current ratio
- 12.88
Cash generation0 / 20
Consumes cash and must keep raising it.
- Operating cash flow
- -$125.0M
- Free cash flow
- -$126.6M
- FCF margin
- -5596.9%
Dilution & runway0 / 20
Heavy dilution — shareholders are paying for the business.
- Shares outstanding
- 123.6M
- Share growth (1y)
- 6025.7%
- Cash runway
- 50 months
Five pillars — profitability, leverage, liquidity, cash generation, dilution & runway — each scored 0–20 from the company’s own income statement, balance sheet and cash-flow statement, then scaled to 100. A pillar the statements cannot answer is left out rather than guessed; fewer than three and no score is shown.
PBLS Income Statement
| Fiscal Period | Q3 2026 | Q2 2026 | Q1 2026 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Period Ending | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | $2.11 M | $148.00 K | $0.00 | $0.00 | $0.00 |
| Revenue Growth (YoY) | — | — | — | — | — |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $618.00 K | $0.00 |
| Gross Profit | $0.00 | $148.00 K | $0.00 | -$618.00 K | $0.00 |
| SG&A Expense | $11.25 M | $11.66 M | $9.70 M | $5.78 M | $6.34 M |
| R&D Expense | $45.60 M | $39.38 M | $37.75 M | $30.13 M | $33.91 M |
| Operating Expenses | $56.85 M | $51.03 M | $47.45 M | $35.90 M | $40.24 M |
| Operating Income | -$54.74 M | -$50.89 M | -$47.45 M | -$36.52 M | -$40.24 M |
| Pretax Income | -$44.49 M | -$52.46 M | -$45.32 M | -$34.81 M | -$38.33 M |
| Tax Provision | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$44.49 M | -$52.46 M | -$45.32 M | -$34.81 M | -$38.33 M |
| EPS (Basic) | -$0.36 | -$2.32 | -$34.58 | -$0.36 | -$23.84 |
| EPS (Diluted) | -$0.36 | -$2.32 | -$34.58 | -$0.36 | -$23.84 |
| Shares Outstanding | 123.59 M | 28.91 M | 2.05 M | 2.02 M | 2.02 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.